GlassScriptPhysician profile
Ashley M Ray
NPI 1619338605
$2,446.08
in general payments reported to CMS, 2019-2025
28 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $314 · 2022: $205 · 2023: $360 · 2024: $334 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,839 · Education: $87.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.08 |
| Education | $87.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.86 | 2021-2023 | Rybelsus, Ozempic |
| Viatris Specialty LLC | $195.82 | 2025 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $190.29 | 2025 | Lumryz |
| Glaxosmithkline, LLC. | $163.21 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Harmony Biosciences LLC | $155.01 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $146.39 | 2024-2025 | Tezspire, Airsupra, Fasenra |
| Verona Pharma, INC. | $139.15 | 2025 | Ohtuvayre |
| Inari Medical, INC. | $135.83 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $111.74 | 2021-2025 | Repatha, Tezspire, Repatha |
| Inspire Medical Systems, INC. | $111.40 | 2023-2025 | Inspire |
| Abbvie INC. | $106.98 | 2021-2022 | |
| Mylan Specialty L.P. | $104.72 | 2024 | Yupelri |
| Philips North America LLC | $98.62 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Incourage Airway Clearance Therapy |
| Genzyme Corporation | $71.15 | 2025 | |
| Biosense Webster, INC. | $64.52 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $62.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.22 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $51.89 | 2025 | Mounjaro, Zepbound |
| Acclarent, INC | $51.37 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $46.68 | 2025 | |
| Inogen, INC. | $31.48 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.66 | 2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.04 | 2025 | Jascayd |
| Abbott Laboratories | $22.63 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $21.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.43 | 2022 | |
| Merck Sharp & Dohme LLC | $14.86 | 2022 | |
| Smith+Nephew, INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.